5PSQ-065 Prediction of toxicity of methotrexate by means of genetic tests in patients diagnosed with moderate–severe psoriasis

Background and importanceMethotrexate is the standard treatment for moderate–severe psoriasis. However, it is a very aggressive treatment which has a high percentage of severe adverse events, such as asthenia, gastrointestinal toxicity, haematological toxicity and nephrotoxicity. This toxicity profi...

Full description

Saved in:
Bibliographic Details
Published in:European journal of hospital pharmacy. Science and practice 2020-03, Vol.27 (Suppl 1), p.A179-A180
Main Authors: Membrive, C, Perez Ramírez, C, Márquez Pete, N, Maldonado Montoro, MDM, Arias Santiago, SA, Jimenez Morales, A, Ramirez Tortosa, MDC
Format: Article
Language:English
Subjects:
Alcoholism
Diabetes
Health risk assessment
Psoriasis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and importanceMethotrexate is the standard treatment for moderate–severe psoriasis. However, it is a very aggressive treatment which has a high percentage of severe adverse events, such as asthenia, gastrointestinal toxicity, haematological toxicity and nephrotoxicity. This toxicity profile varies from person to person. Various studies have reported that these interindividual differences may be due to genetic factors, such as single nucleotide polymorphisms (SNPs), which are involved in methotrexate pharmacodynamics, metabolism and mechanism of action.Aim and objectivesTo determine the utility of ABCB1 C3435T and MTHFR 1298 as prognostic and predictive markers in patients diagnosed with moderate–severe psoriasis treated with methotrexate, and to evaluate the toxicity of methotrexate treatment.Material and methodsA prospective cohort study was performed. Data and DNA were obtained from saliva samples of 64 patients residing in the province of Granada with moderate–severe psoriasis who had been treated with methotrexate. The genotypes were determined by Taqman PCR real time.ResultsMean age of the patients was 46±14 years; 33 men (33/64); 57 had psoriasis plaque (57/64), 56 located in the trunk and extremities and 30 in the scalp and face, 17 had psoriatic arthritis (29/64), 7 with diabetes mellitus (7/64), there were 19 smokers (19/64), 16 occasional drinkers (16/64) and 30 had a family history of psoriasis (30/64). Twenty-eight patients were treated with oral administration of methotrexate (28/64) and 44 for
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2020-eahpconf.382